GlassScriptPhysician profile
Nolan R Gartin
NPI 1437564721
$2,401.66
in general payments reported to CMS, 2019-2025
27 companies · $825 in 2025
The $825 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $62.85 · 2023: $633 · 2024: $881 · 2025: $825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,338.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $334.66 | 2022-2025 | Rexulti, Abilify Maintena |
| Novo Nordisk INC | $306.16 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $249.73 | 2023-2025 | Farxiga, Airsupra, Flumist Quadrivalent |
| Teva Pharmaceuticals USA, INC. | $180.66 | 2023-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $152.50 | 2024-2025 | Fanapt, Hetlioz |
| Amgen INC. | $148.55 | 2023-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $116.53 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $114.82 | 2025 | Caplyta |
| Abbvie INC. | $101.86 | 2022-2023 | |
| Lilly USA, LLC | $98.10 | 2023-2025 | Mounjaro, Jardiance, Trulicity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.17 | 2024-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $74.56 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $59.98 | 2024-2025 | Veozah |
| Lundbeck LLC | $59.35 | 2023-2025 | Rexulti |
| Sumitomo Pharma America, INC. | $53.23 | 2023-2025 | Gemtesa |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $50.30 | 2023-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.24 | 2023 | Spiriva Respimat, Tradjenta, Synjardy |
| Eisai INC. | $25.04 | 2024 | |
| Dexcom, INC. | $24.38 | 2024 | Dexcom G6 Transmitter |
| Organon LLC | $22.37 | 2023 | Nexplanon |
| Neurocrine Biosciences, INC. | $20.79 | 2024 | Ingrezza |
| Nevro Corp. | $17.98 | 2023 | Senza |
| Viatris Specialty LLC | $17.22 | 2025 | Yupelri |
| Pfizer INC. | $14.95 | 2023 | |
| Electromed, INC. | $14.21 | 2024 | Smartvest |
| Merck Sharp & Dohme LLC | $13.86 | 2025 | Capvaxive, Gardasil 9 |
| Boston Scientific Corporation | $13.46 | 2025 | Watchman Flx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nolan Gartin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.